Abstract library

1222 results for "second line treatment".
#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: M.D. Ingrid Holst Olsen
#1211 Lack of Efficacy of Anthracycline-Containing Second Line Chemotherapy in Patients with GI-NEC After Cisplatin-Based Treatment
Introduction: Little is known about optimal 2nd-line treatment in patients with GI-NEC failing cisplatin-based therapy.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Barbara Kiesewetter
Keywords: GI-NEC
#1496 Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-differentiated Neuroendocrine Tumors Resistant to Prior Treatments
Introduction: Alternating treatment with sunitinib and everolimus, has been shown to be efficacious in renal cell carcinoma
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Angelousi
#1750 Sunitinib as First Line Therapy in Patients with Advanced Pancreatic Neuroendocrine Tumors: Experience of a Single Algerian Center
Introduction: Sunitinib is indicated in the treatment of patients with advanced progressive pancreatic neuroendocrine tumors (pNETs).Its experience as first line therapy is limited.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: doctor Belabdi Djihed
Authors: Djihed B, Alyda M, Mohammed O, ...
#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)
Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Raymond
#1240 Targeted Therapies as First Line Option in Very Advanced Unresectable Pancreatic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors are an entity of rare, heterogeneous group of tumors that can arise from different sites within the body. Although number of different treatment types and modalities exist, chemotherapy remains as the first line option in the management of advance pancreatic NETS (pNETS); two targeted therapies, sunitinib and everolimus remains available only for second line and beyond in Canada.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Young Soo Rho
Authors: Rho Y S, Gilabert M, McLean J, Kavan P, ...
#1413 Everolimus (EVE) Treatment for Advanced G1-G2 Neuroendocrine Tumours (NETs) in the Community Setting: Clinical Benefit Irrespective of Previous Therapies
Introduction: Randomized studies have shown EVE has antitumour activity in advanced G1-G2 NETs. However, data outside regulatory trials are limited.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD PhD Ana Custodio
#891 Metastatic G1-G2 Neuroendocrine Tumors (WDNET) Treated with Sequences of Different Somatostatine Analogs (SSA) - Lanreotide LAR (La), Octreotide LAR (Oc): A Single Center Experience
Introduction: PROMID and CLARINET trials demonstrate an improvement in PFS of SSA v. placebo in WDNET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Riccardo Marconcini
#2100 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Neuroendocrine Tumors Starting Lanreotide – Study Design
Introduction: Information provided to patients about burden and treatment of neuroendocrine tumors (NETs) may ease treatment adherence, outpatient monitoring, and improve quality of life (QoL), but can also cause anxiety. Data on how to individually adapt materials are insufficient and mainly derived from clinical trials.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Vincent Hautefeuille
Authors: Gueguen D, Hammel P, ...
#402 Single-Center Treatment Outcomes in Patients (pts) with High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC)
Introduction: cNEC is a rare and aggressive cancer; the best treatment is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Boris Naraev
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.